These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34378062)

  • 1. Neurological involvement in children with hemolytic uremic syndrome.
    Costigan C; Raftery T; Carroll AG; Wildes D; Reynolds C; Cunney R; Dolan N; Drew RJ; Lynch BJ; O'Rourke DJ; Stack M; Sweeney C; Shahwan A; Twomey E; Waldron M; Riordan M; Awan A; Gorman KM
    Eur J Pediatr; 2022 Feb; 181(2):501-512. PubMed ID: 34378062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.
    Rosales A; Kuppelwieser S; Giner T; Hofer J; Riedl Khursigara M; Orth-Höller D; Borena W; Cortina G; Jungraithmayr T; Würzner R;
    Pediatr Nephrol; 2024 Aug; 39(8):2459-2465. PubMed ID: 38589699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outbreak of hemolytic uremic syndrome with unusually severe clinical presentation caused by Shiga toxin-producing Escherichia coli O26:H11 in France.
    Minary K; Tanne C; Kwon T; Faudeux C; Clave S; Langevin L; Pietrement C; Enoch C; Parmentier C; Mariani-Kurkdjian P; Weill FX; Jones G; Djouadi N; Morin D; Fila M
    Arch Pediatr; 2022 Aug; 29(6):448-452. PubMed ID: 35662540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage.
    Luna M; Kamariski M; Principi I; Bocanegra V; Vallés PG
    Pediatr Nephrol; 2021 Jun; 36(6):1499-1509. PubMed ID: 33205220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement.
    Wildes DM; Harvey S; Costigan CS; Sweeney C; Twomey É; Awan A; Gorman KM
    Pediatr Nephrol; 2024 Jan; 39(1):315-324. PubMed ID: 37491519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
    Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
    Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
    Ylinen E; Salmenlinna S; Halkilahti J; Jahnukainen T; Korhonen L; Virkkala T; Rimhanen-Finne R; Nuutinen M; Kataja J; Arikoski P; Linkosalo L; Bai X; Matussek A; Jalanko H; Saxén H
    Pediatr Nephrol; 2020 Sep; 35(9):1749-1759. PubMed ID: 32323005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
    Khalid M; Andreoli S
    Pediatr Nephrol; 2019 Dec; 34(12):2495-2507. PubMed ID: 30382336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.
    Pape L; Hartmann H; Bange FC; Suerbaum S; Bueltmann E; Ahlenstiel-Grunow T
    Medicine (Baltimore); 2015 Jun; 94(24):e1000. PubMed ID: 26091445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.
    Ardissino G; Vignati C; Masia C; Capone V; Colombo R; Tel F; Daprai L; Testa S; Dodaro A; Paglialonga F; Luini M; Brigotti M; Picicco D; Baldioli C; Pagani F; Ceruti R; Tommasi P; Possenti I; Cresseri D; Consonni D; Montini G; Arghittu M;
    J Pediatr; 2021 Oct; 237():34-40.e1. PubMed ID: 34197890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume expansion mitigates Shiga toxin-producing E. coli-hemolytic uremic syndrome in children.
    Böckenhauer J; Schild R; Kemper MJ; Henne T; Stein MV; Oh J; Loos S
    Pediatr Nephrol; 2024 Jun; 39(6):1901-1907. PubMed ID: 38240870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008.
    Jenssen GR; Vold L; Hovland E; Bangstad HJ; Nygård K; Bjerre A
    BMC Infect Dis; 2016 Jun; 16():285. PubMed ID: 27297224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Plasma Exchange Efficacious in Shiga Toxin-Associated Hemolytic Uremic Syndrome? A Narrative Review of Current Evidence.
    Keenswijk W; Raes A; De Clerck M; Vande Walle J
    Ther Apher Dial; 2019 Apr; 23(2):118-125. PubMed ID: 30324646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
    Wijnsma KL; Schijvens AM; Rossen JWA; Kooistra-Smid AMDM; Schreuder MF; van de Kar NCAJ
    Pediatr Nephrol; 2017 Jul; 32(7):1263-1268. PubMed ID: 28343354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Treatment for Shiga Toxin-Producing
    Liu Y; Thaker H; Wang C; Xu Z; Dong M
    Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Post-diarrheal haemolytic uremic syndrome: when shall we consider it? Which follow-up?].
    Bertholet-Thomas A; Ranchin B; King LA; Bacchetta J; Belot A; Gillet Y; Collardeau-Frachon S; Cochat P
    Arch Pediatr; 2011 Jul; 18(7):823-30. PubMed ID: 21571510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.
    Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R;
    Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemolytic uremic syndrome caused by Shiga-toxin-producing Escherichia coli].
    Loirat C
    Rev Prat; 2013 Jan; 63(1):11-6. PubMed ID: 23457821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.